The current study aims to identify the pro-fibrogenic role of Gremlin, an endogenous antagonist of bone morphogenetic proteins (BMPs) in chronic pancreatitis (CP). CP is a highly debilitating disease characterized by progressive pancreatic inflammation and fibrosis that ultimately leads to exocrine and endocrine dysfunction. While transforming growth factor (TGF)-β is a known key pro-fibrogenic factor in CP, the TGF-β superfamily member BMPs exert an anti-fibrogenic function in CP as reported by our group recently. To investigate how BMP signaling is regulated in CP by BMP antagonists, the mouse CP model induced by cerulein was used.
Introduction
Pancreatitis is an extremely painful disease with severe complications. It is a major contributor to the economic burden of gastrointestinal diseases in the USA, with estimated costs in 2004 at $3.7 billion [1] . Following an initial acute pancreatitis admission, 16 % of patients progress to chronic pancreatitis (CP); this number increases to 38 % following a second admission [2] . As fibrosis progresses, organ dysfunction ensues as acinar and islet cells are lost. CP is also a major risk factor for pancreatic cancer, a diagnosis with survival rates less than 7 %. Pancreatic cancer is currently the fourth leading cause of cancer deaths in the USA and is projected to surpass colorectal cancers to become the second leading cause of cancer deaths by 2030 [3] . However, currently, there are no effective therapies to stop or reverse CP progression [4] .
During CP progression, pancreatic stellate cells (PSCs) are activated by pro-fibrogenic cytokines and differentiate into myofibroblast-like cells elaborating excessive extracellular matrix (ECM) deposition and leading to fibrosis [5] . As a key pro-fibrogenic cytokine in CP, transforming growth factor (TGF)-β binds to the transmembrane receptors on PSCs, subsequently phosphorylates Smad2/3, and leads to PSC activation and ECM production. In contrast, bone morphogenetic proteins (BMPs), a major subgroup of the TGF-β superfamily, are anti-fibrogenic in the lungs, kidneys, and liver [6] [7] [8] [9] . They act by binding cell surface receptors and phosphorylating Smad1/5/8. Recently, we reported that in the pancreas, BMP signaling constitutes an opposing mechanism to TGF-β's pro-fibrogenic function; BMP signaling is impaired in CP, which is associated with enhanced TGF-β signaling, resulting in disease progression [10, 11] . However, the mechanisms that regulate BMP signaling in CP are unknown. Gremlin (specifically Grem1), an endogenous BMP antagonist, is the product of Grem1, a highly conserved member of the DAN/cerberus family glycoprotein important in development [12] . Its expression is increased in fibrotic diseases of the lungs [7] , kidneys [13] , and liver [14] as well as various malignancies [15] . In vitro, TGF-β stimulates Gremlin expression in bronchial and kidney epithelial cells [7, 16] . Knockdown of Grem1 in vivo by siRNA inhibits ECM accumulation in a mouse model of diabetic nephropathy [17] . Depletion of Grem1 expression protects Grem1 +/− mice from kidney fibrosis [18] . These findings suggest that Grem1 is required for the development of organ fibrosis.
In the current study, we found that Grem1 was elevated following an elevation of TGF-β1 in CP. We hypothesize that TGF-β-induced Grem1 blocks BMP signaling and function, which composes a novel mechanism for CP progression. This study thus aimed to test if Grem1 expression in the pancreas promotes pancreatic fibrosis during CP progression. We found that Grem1 knockout in Grem1 +/− mice attenuated pancreatic fibrosis in CP compared to wild-type littermates. In vitro in isolated PSCs, TGF-β induced Grem1 expression, and Grem1 blocked BMP signaling and anti-fibrogenic function. Our data indicate that Grem1 is pro-fibrogenic by antagonizing BMP activity in CP. Thus, strategies to block Grem1 may represent innovative therapies for CP. +/− ) were obtained through Jackson Laboratory (Bar Harbor, ME, USA). Colonies of Grem1 +/− were maintained through crossing male Grem1 +/− mice and female wild-type C57BL/6J mice (Jackson Laboratory); offsprings were genotyped by PCR [12] . Male and female mice were utilized for experiments at the age of 8-10 weeks. All animal experiments were performed in accordance with Animal Welfare Committees of The University of Texas Health Science Center at Houston and the University of Texas Medical Branch at Galveston.
Materials and methods

Reagents
Mice were randomized into either a CP or control group. CP was induced by repetitive intraperitoneal injections of cerulein (50 μg/kg, five hourly injections/day, 3 days/week) for up to 8 weeks as previously reported [10, 11] . Control mice were given saline injections of the same volume and frequency. At days 3-4 following completion of cerulein or saline injections, the mice were euthanized, and the pancreata were harvested for analysis.
Quantitative PCR
Total RNAwas extracted from pancreatic tissue samples of the mice or cells and reversely transcribed to complementary DNA (cDNA) using RETROscript kit (Life Technology Co., Grand Island, NY, USA). Quantitative PCR (qPCR) was performed using TaqMan gene expression master mix and specific gene probe sets as previously described [19] . The probe sets of mouse TGF-β1 (Mm01178820_m1), Grem1 (Mm00488615_s1), Noggin (Mm01297833_s1), Chordin1 (Mm00473158_m1), Col1a1 (Mm00801666_g1), and 18S (Hs99999901_s1) (Life Technology Co., Grand Island, NY, USA) were used in the study. The specific signals acquired were normalized to the signals acquired from 18S.
Human pancreas samples
Following the guidelines of the University of Texas Medical Branch at Galveston, the human pancreata were obtained from cadavers and from discarded pancreatic tissue from surgical resection.
Immunohistochemistry analysis
Pancreas sections (5 μm thick) were prepared for immunohistochemical (IHC) analysis of Grem1 with ABC and DAB kits from Vector Laboratories, Inc. (Burlingame, CA, USA) according to the manufacturer's instructions and as previously described [10, 11] . Following staining, five to eight random, non-overlapping fields per section were captured for analysis. Two to three investigators blinded to sample identity evaluated the staining images according to the criteria previously published for human samples [20] [21] [22] or for mouse pancreas samples [10, 11] .
Quantitative analysis of pancreatic fibrosis
Sirius red staining was performed on pancreas sections for analysis of collagen deposition [23] . A minimum of 15-20 non-overlapping fields were captured from each section. Sirius red-stained area was quantified with NIS-Elements Br 3.0 software. Stained areas were calculated as a percentage of total tissue area analyzed and expressed as fold of control [10] .
Western blotting
Western blotting was conducted as previously described [19] . Protein lysates were prepared from mouse pancreas and cells in 1× lysis buffer (Cell Signaling Technology, Billerica, MA, USA), and protein concentration was measured with a protein assay dye (Bio-Rad Laboratories, Hercules, CA, USA). Blots were probed with indicated primary antibodies, bound primary antibodies were detected with horseradish peroxidaseconjugated secondary antibodies, and signals were visualized with enhanced chemiluminescent reagents (Thermo Scientific).
Isolation and culture of PSCs
Mouse primary PSCs (mPSCs) were isolated from mouse pancreata (8-10 weeks old) using an outgrowth method [11, 24] . Isolated mPSCs were pooled from three to four mice. The PSCs were seeded and cultured at 37°C in a humidified incubator (containing 95 % O 2 and 5 % CO 2 ). PSCs were grown to 60-80 % confluence and starved for 18-20 h in a medium supplemented with 0.1 % serum before the respective treatments.
Immunofluorescence
The PSCs were treated, alone or in combination, with respective proteins, or vehicle. After 48 h, PSCs were fixed with 4 % paraformaldehyde for 15 min. Immunofluorescence (IF) was performed using specific antibodies as previously described [11] .
Statistical analysis
Data are expressed as mean±standard error (SEM). P value <0.05 is considered as significant. In vitro experiments were repeated two to three times, and similar results were obtained. Differences between two groups were analyzed using Student's t test. Differences among multiple groups were analyzed using ANOVA with Holm-Sidak post hoc test.
Results
Grem1 mRNA expression increases along with increased TGF-β1 expression in CP As TGF-β is reported to influence expression of BMP antagonists in other tissues, investigation began in a mouse model of CP with a survey of pancreatic TGF-β1 and BMP antagonist messenger RNA (mRNA) expression (Fig. 1) . TGF-β1 mRNA levels were dramatically elevated during CP induction at 1 week (136-fold), 2 weeks (156-fold), and 3 weeks (35-fold) and decreased following the recovery period. Increased TGF-β1 mRNA levels were associated with increased expression of Grem1, Noggin, and Chordin1 mRNAs following CP induction. Grem1 expression demonstrated the greatest induction of the investigated BMP antagonists, peaking at 145-fold following 3 weeks of treatment, while expression of Noggin and Chordin1 peaked before Grem1 expression. The predominant elevation of Grem1 over Noggin and Chordin1 suggests that Grem1 may be the major BMP antagonist responsible for blocking BMP signaling during the development of CP.
Elevated Grem1 protein levels correlate with fibrosis in cerulein-induced CP mouse model
To investigate the temporal relationship of Grem1 expression in CP and progression of fibrosis, cerulein injections in the mouse model were performed through 8 weeks. Saline injections were given in control mice. Sirius red staining was conducted to quantify collagen deposition (Fig. 2) along the time course for correlation with Grem1 elaboration by IHC (Fig. 3) . Collagen area was unchanged in control mice but trended upward in CP mice throughout the time course, with significant increases versus time-matched control beginning at 4 weeks of treatment (Fig. 2) . Grem1 expression was increased significantly in CP mice after 1 week of treatment, peaked at 4 weeks, and remained elevated through 8 weeks; expression in the control group remained minimal throughout (Fig. 3a, b) . Western blotting of Grem1 supports the IHC findings, demonstrating that Grem1 protein levels increased in CP mice at 2 and 4 weeks compared to the controls (Fig. 3c, d ). These data demonstrate that Grem1 protein expression is upregulated in the CP mouse model during the development of fibrosis.
Grem1 protein expression increases in human CP
It has been previously reported that Gremlin expression is upregulated in fibrotic disease of the lungs, kidneys, and liver [7, 13, 14, 16] . We, therefore, set about correlating our mouse model findings in the pancreas with human disease via investigation of human CP pancreata. Analysis of immunohistochemistry showed that Grem1 expression was low in normal pancreata but significantly upregulated in the pancreata of CP patients (Fig. 4) . Furthermore, pSmad1/5 IHC with the same set of human samples showed a moderate reduction of pSmad1/5 in CP versus the normal pancreas (P>0.05). These indicate that Grem1 is upregulated in human CP, which corroborates mouse model findings and validates the study as clinically relevant in investigating Grem1 in pancreatic fibrosis in CP.
Grem1 haplodeficiency attenuates cerulein-induced fibrosis
Numerous factors may be involved in the maintenance of tissue architecture in response to pancreatic injury during CP induction. To identify the Grem1-dependent portion of pancreatic fibrosis in CP in vivo, a mutant mouse line with heterozygous Grem1 knockout (Grem1 +/− ) that underwent CP induction was constructed for analysis as homozygous Grem1 knockout is lethal and thus not available. Adult Grem1 +/− mice were phenotypically normal compared to wild-type (WT) littermates prior to CP induction. Sirius red staining showed no difference in collagen deposition between saline control Grem1 +/− and WT; following CP induction for 4 weeks, however, collagen deposition in Grem1 +/− mice was reduced by 33.2 % compared to WT (Fig. 5) . These indicate a pro-fibrogenic role of Grem1 in the pancreas.
TGF-β induces Grem1 in mPSCs
We have demonstrated that the peak elevation of TGF-β1 during CP induction in vivo precedes Grem1 (Fig. 1) , allowing for induction of Grem1 expression by TGF-β. To examine whether TGF-β has a direct effect on Grem1 expression in PSCs in vitro, mPSCs were isolated and treated with TGF-β1 (1 ng/ml) for either 24 h for evaluation of mRNA levels by qPCR or 48 h for measurement of protein levels by Western blotting and IF. Treatment with TGF-β1 increased Grem1 mRNA levels by 1.8-fold (Fig. 6a ) and Grem1 protein levels by 2.3-fold in Western blotting (Fig. 6b) . The blots were probed with the Grem1 antibody with and without pre-incubation of the recombinant Grem1 protein. Optical densities of the reported Grem1 protein band at the size around 25 kDa reduced to 52 % in the PSC samples and to 45 % in the recombinant Grem1 protein when probed with the Grem1 antibody pre-incubated with the recombinant protein, compared to the Grem1 antibody alone (Fig. 6c) , Fig. 1 CP increases expression of pancreatic TGF-β1 and BMP antagonists. Pancreata were harvested from C57BL/6 mice following 1, 2, or 3 weeks CP induction with cerulein or after 5 weeks recovery following 3 weeks CP induction (3w+5w recovery). Total RNAs were extracted and converted to cDNAs. mRNA expression levels of TGF-β1, Grem1, Noggin, and Chordin1 were measured by qPCR. The specific signals were normalized against 18S rRNA and expressed as fold of respective 0 week expression levels (mean±SEM). n=5-9/group. *P<0.05 compared with respective 0 week using one-way ANOVA and multiplecomparison test (Dunn's method) demonstrating a partial blocking of the signals in the presence of the recombinant protein. These findings confirmed Grem1 protein size at around 25 kDa as reported.
Treatment with TGF-β1 induced Grem1 expression in mouse PSCs (Fig. 6d) . Thus, our data indicate a direct induction of Grem1 by TGF-β in mPSCs. 
Grem1 blocks the anti-fibrogenic effects of BMP2 in mPSCs
We reported recently that BMP signaling is anti-fibrogenic in the pancreas during CP induction [10, 11] . In this study, we attempted to test our hypothesis that elevated Grem1 expression in CP imposes antagonism of the anti-fibrogenic BMP signaling, thereby enhancing pancreatic fibrosis. First, the dose effects of Grem1 on BMP2-induced Smad1/5 signaling were evaluated by Western blotting (Fig. 7a) . BMP2 induced a 16.2-fold increase of pSmad1/5. This effect was inhibited 62 % by the recombinant Grem1 at 50 ng/ml and abolished at 500 ng/ml. Thus, Grem1 dose of 500 ng/ml was used in later experiments. Western blotting was then conducted to evaluate Smad1/5 signaling following treatment of mPSCs with TGF-β1, BMP2, and/or Grem1. Treatment with TGF-β1 did not significantly induce pSmad1/5 levels or affected BMP2-induced pSmad1/5. Grem1 blocked BMP2-induced pSmad1/5 (Fig. 7b) . To investigate the effects of BMP signaling inhibition on fibrosis, mRNA and protein expressions of Col1a1 were conducted following similar treatments as a functional readout of fibrosis. TGF-β increased Col1a1 mRNA expression by 2.0-fold, and BMP2 blocked TGF-β-induced Col1a1 mRNA expression. Addition of Grem1 restored Col1a1 mRNA expression otherwise attenuated by BMP2, with Col1a1 mRNA expression similar to TGF-β treatment alone (Fig. 7c) . The same pattern was also observed on Col1a1 protein expression by IF (Fig. 7d) . Together, these findings demonstrate a pro-fibrogenic effect of Grem1 in the pancreas through antagonism of BMP signaling.
Discussion
Chronic pancreatitis stems from a variety of initial insults to the exocrine pancreas, after which counterbalancing signaling normally serves to maintain pancreatic function and structure tip excessively toward a pro-inflammatory and pro-fibrogenic milieu. Via human and genetic knockout animal studies Among BMP antagonists, Gremlin has been reported to play a pro-fibrogenic role in the kidneys, lungs, and liver [7, 13, 14, 16] . This is indeed the case in our study that the levels of Grem1 are predominantly elevated and sustained in CP in comparison with other BMP antagonists, Noggin and Chordin1, examined (Fig. 1) . The evidences of Grem1's pro-fibrogenic function provided in our study through human CP and an animal CP model further our knowledge of the pathogenic role of Grem1 in fibrotic diseases.
Concentrations of BMP2 and Grem1 utilized in the current study were chosen based on the TGF-β concentration (1 ng/ml) we have reported as a stimulant of fibrosis in vitro [11] . Accordingly, the BMP2 concentration used is an optimal concentration to abolish TGF-β's effects on ECM production. The dose of the recombinant Grem1 at 500 ng/ml used in this study was necessary to abolish BMP2-induced Smad1/5 phosphorylation and BMP's anti-fibrogenic effects. This Grem1 concentration is also relevant to natural levels of Gremlin as reported in human serum as 508 ng/ml and in human plasma as 349 ng/ml [25, 26] . Furthermore, Grem1 at 500 ng/ml did not induce phosphorylation of VEGFR2 in mPSCs (data not shown). However, off-target effects of Grem1 via other receptors cannot be excluded.
Others have postulated mechanisms by which Gremlin drives fibrosis in other organ systems, identifying a central role for Gremlin in hypoxia-induced pulmonary hypertension by antagonism of anti-fibrogenic BMP signaling [27] and in chronic kidney disease [13] . We have also established through a BMPR2 knockout study that BMP signaling is important in protecting against pancreatic fibrosis [10] . Furthermore, our current studies demonstrate a pro-fibrogenic role for Grem1 in driving pancreatic fibrosis via blockade of BMP signaling and function. Our studies indicate a connection between profibrogenic TGF-β signaling and anti-fibrogenic BMP via Grem1 in pancreatic fibrosis.
Understanding of Gremlin's role in physiology and diseases is evolving, and it is increasingly implicated not only in ECM regulation but also in vascular homeostasis. It is of growing interest in tumor biology not only for its upregulation antibody or neutralized Grem1 antibody. +T: mPSCs treated with TGF-β1 for 48 h. rGrem1: recombinant mouse Grem1 protein as a positive control. d Representative merged images of IF using antibodies against Grem1 (green) with DAPI nuclear staining (blue). Scale bar represents 100 μm. Quantification of IF is expressed as fold of Veh and presented as mean±SEM. n=5-10 independent fields/slide. *P<0.05 compared to Veh using Student's t test in numerous carcinomas and promotion of cancer cell survival and expansion [28] [29] [30] but also for its novel role as a vascular endothelial growth factor type 2 receptor (VEGFR2) agonist [31] . What role of VEGFR2-mediated cascade may have played in our study is unknown, and another study will seek to further this understanding. As evidence for Gremlin's role in chronic fibrotic processes and as tumor biology continues to grow more robust, our study suggests a potential link between pancreatitis and pancreatic cancer via Grem1. Thus, investigation of Grem1-targeting therapies potentially serves both development for CP therapy and prevention of pancreatic cancer.
In summary, evidence reported here demonstrates that Grem1 expression in the pancreas is dynamic and induced in the diseased state. It promotes fibrosis by blocking BMP signaling to dampen anti-fibrogenic signal transduction. Grem1 may represent a novel target for stemming fibrotic disease progression in human subjects. Given the normally low expression of Grem1 in the pancreas, future work may seek to specifically block Grem1 synthesis and activity and/or enhance BMP signaling through pharmaceutical therapies. If such therapies are developed, they may be applicable as early interventions to prevent CP progression and its sequelae.
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